An interventional study of Polysomnography in Multiple Sclerosis and Respiration Disorders, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Other
Among 376 studies in Multiple Sclerosis with a site in France — 64 open to participants now, 93 under way, 18 of them phase 3. Multiple Sclerosis · France.
Among the 376 studies in Multiple Sclerosis with a site in France, this one is the 168th largest by enrollment of the 244 interventional ones that give a count, is one of 24 that started in 2018, is one of 110 with no phase, and was the 164th registered.
3,267 studies on the registry are indexed under Multiple Sclerosis; 662 are open to participants now.
Browse Multiple Sclerosis studies →64 of the 376 studies in Multiple Sclerosis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 18–65
University Hospital, Montpellier · Sites in France
Ages 40+
University Hospital, Caen · Sites in France
Ages 18+
Otto Bock France SNC · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
376 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 28 · Phase 3 77 · Phase 4 25
First in 1999; this study’s year is marked. 24 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is above the median of 50 across 2,203 interventional studies indexed under Multiple Sclerosis.
Median enrollment 144 across the 244 interventional studies, 174 across the 132 observational. Of the 253 that completed or were terminated, 69 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 376 have an industry lead sponsor. The 10 most frequent:
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Institut National de la Santé Et de la Recherche Médicale, France has 6 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
18 of the studies in Multiple Sclerosis with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT03653273Phase 3Rennes University HospitalDisease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) | 2027-07 |
| NCT05519553Nantes University HospitalPeer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis | 2026-12-01 |
| NCT07108088ÖSSUR FranceEvaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application | 2026-12-31 |
| NCT05772637Assistance Publique - Hôpitaux de ParisClinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis | 2027-02-14 |
Add all 18 to your calendar (.ics) → With an account.
Among the 376 studies in Multiple Sclerosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to describe respiratory disorders in patients with severe multiple sclerosis (EDSS from 6.5).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
polysomnography and functional pulmonary testings.
Diagnostic Test: Polysomnography
During polysomnographia and functional pulmonary testing, signs of diaphragmatic dysfunction responsible for respiratory disorders will be searched.
Also known as: functional pulmonary testings
Polysomnography
presence of phasic activation of respiratory muscles
Time frame: Baseline only_during one night
Respiratory function testing
difference between vital capacity upright and supine position (liter)
Time frame: Baseline only
Respiratory function testing
maximal inspiratory pressure (mmHg)
Time frame: Baseline only
Respiratory function testing
maximal expiratory pressure (mmHg)
Time frame: Baseline only
Respiratory function testing
SNIP (mmHg)
Time frame: Baseline only
Respiratory function testing
peak flow (liter)
Time frame: Baseline only
Cerebral and cervical spine MRI
cerebral : 3DT1MPRAGE, T2 FLAIR, DWI / spine: 3DT1MPRAGE, axial T2 MEDIC, T2-WSPACE
Time frame: Baseline only
Expanded Disability Status Scale (EDSS)
Neurological assessment of disability related to multiple sclerosis, total score from 0 to 10
Time frame: Baseline only
BICAMS
Brief International Assessment for Multiple Sclerosis
Time frame: Baseline only
Ran from Jan 2018 to primary completion in Nov 2020, 33 months.
Of 848 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 33 months is above that.
Counting every sponsor, half of 870 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →